Dear Editor,

The novel coronavirus (COVID-19) outbreak has been declared a global pandemic. The containment measures implemented in recent weeks to tackle it have led to drastic alterations in people’s daily life. These changes were essential to reduce virus transmission and protect health systems\(^1\).

However, lockdown and strict measures, including home quarantine and social distancing, have delayed the diagnosis or postponed the therapeutic management of patients with neoplasia, such as surgery, systemic chemotherapy and radiation. On the other hand, COVID-19 exposure may have adverse outcomes in patients with cancer because of their systemic immunosuppression caused by the malignancy or anticancer treatment methods\(^2\).

We present a bizarre case of delay in the treatment of a woman with endometrial cancer. A 79-year-old Caucasian woman presented to our outpatient department in May 2020 with a diagnosis of endometrial cancer since February 2020. Endometrial cancer was diagnosed in a secondary institution by dilation and curettage due to postmenopausal vaginal bleeding. Histopathology revealed a malignant mixed Müllerian tumor. The epithelial component was compatible with a grade 3 endometrioid adenocarcinoma. Pretreatment clinical staging tests including chest X-ray, ultrasound and magnetic resonance imaging scan of the pelvis were performed. Significant finding was endometrial cancer with invasion of more than half of myometrium, clinical stage IB. Thus, patient was referred to a tertiary hospital.

Meanwhile the lockdown was implemented in Greece, therefore the patient along with her family members decided to postpone the clinic appointment to our department, in order to reduce the risk of viral transmission.

In May 2020, while COVID-19 lockdown measures were gradually eased the patient presented to our outpatient department. On admission, the patient described that during the home quarantine she experienced multiple episodes of vaginal bleeding and she used tranexamic acid orally without a medical prescription. From past medical history, she reported arterial hypertension, diabetes mellitus...
and aortic valve stenosis. Her BMI was 45.4 kg/m². Bimanual pelvic examination revealed heavy vaginal bleeding and transvaginal ultrasonography showed an enlarged uterus with an endometrial thickness of 24mm.

Due to the wait interval of four months and the clinical findings, we also performed a restaging imaging. A contrast enhanced computed tomography scan of abdomen showed an invasion of the left parametrium as well as multiple enlarged pelvic and paraaortic lymph nodes, implying a progression from Stage IB to Stage IIIC.

The multidisciplinary team discussed our case and the patient was disqualified from surgery due to the severity of the disease (FIGO -Stage III) and patient's advanced age and poor general condition; therefore, radiotherapy was recommended. The patient received external pelvic radiotherapy with 16 applications of 250cGy/day (total dose of 4,000 cGy).

It is popularly assumed, that delay in the delivery of treatment for uterine cancer have a negative impact on overall survival3, whilst a study from Israel showed that a delay in treatment of four months do not compromise survival of patients with endometrial cancer4.

Although total hysterectomy with bilateral salpingo-oophorectomy is considered the mainstay treatment for endometrial cancer, our case demonstrates that a delay in the initial evaluation and postponement of the therapeutic management, due to COVID-19 related transmission fear and anxiety in the pandemic process, consequently lead to cancer development, modification of treatment plan and deterioration of patient's prognosis.

Hence, in patients with advanced oncologic disease, the benefit of intervention must be balanced with the risk for potential COVID-19 exposure in health care facilities. Postponement in cancer treatment should be individualized because delay could lead to tumor progression and may affect the ultimate prognosis of patients5.

Conflict of interest
The authors declare no conflict of interest.

References